Curative Biotechnology Inc
OTC:CUBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Curative Biotechnology Inc
Stock-Based Compensation
Curative Biotechnology Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Curative Biotechnology Inc
OTC:CUBT
|
Stock-Based Compensation
$2.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Stock-Based Compensation
$348.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
20%
|
CAGR 10-Years
22%
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
Stock-Based Compensation
$118.4m
|
CAGR 3-Years
56%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Stock-Based Compensation
$147.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Stock-Based Compensation
$483m
|
CAGR 3-Years
29%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
Curative Biotechnology Inc
Glance View
Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2001-07-11. The firm is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The firm's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a immune therapy to treat rabies. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation to treat degenerative eye disease.
See Also
What is Curative Biotechnology Inc's Stock-Based Compensation?
Stock-Based Compensation
2.9m
USD
Based on the financial report for Dec 31, 2021, Curative Biotechnology Inc's Stock-Based Compensation amounts to 2.9m USD.
What is Curative Biotechnology Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 1Y
-33%
Over the last year, the Stock-Based Compensation growth was -33%.
